|
| Status |
Public on Mar 18, 2008 |
| Title |
VB1191 |
| Sample type |
RNA |
| |
|
| Source name |
Breast primary tumor
|
| Organism |
Homo sapiens |
| Characteristics |
status: RF
age: 69.4
adjuvant therapy: X-ray+Tam
histological type: IDC
sbr grade: 2
tumor size (mm): 25
pt (tnm): pT2
lymph node checked: 14
n+: 1
n dich+: 1
pn (tnm): pN1
ER <10
pr: 172
follow-up period (months): 61.5
local recurrence: no
distant metastases: no
time before recurrence (months):
state of health: alive
death cause:
decease delay upon recurrence (months):
decease delay after surgery (months):
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent).
|
| Label |
Cy5
|
| Label protocol |
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).
|
| |
|
| Hybridization protocol |
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays.
|
| Scan protocol |
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software.
|
| Description |
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
|
| Data processing |
Data were median centered and log2 transformed.
|
| |
|
| Submission date |
Dec 14, 2007 |
| Last update date |
Oct 08, 2015 |
| Contact name |
Vincent Negre |
| E-mail(s) |
vincent.negre@valdorel.fnclcc.fr
|
| Organization name |
INSERM
|
| Department |
U896
|
| Street address |
IRCM CRLC Val d'aurelle
|
| City |
Montpellier |
| ZIP/Postal code |
34298 |
| Country |
France |
| |
|
| Platform ID |
GPL5049 |
| Series (1) |
| GSE9893 |
A gene expression signature predicting the recurrence of tamoxifen-treated primary breast cancer. |
|
